<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140004087A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140004087</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13854056</doc-number><date>20130330</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>071</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>0682</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>424 937</main-classification></classification-national><invention-title id="d0e43">ENDOMETRIAL REGENERATIVE CELLS FOR TREATMENT OF TRAUMATIC BRAIN INJURY</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>61618974</doc-number><date>20120402</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>Medistem, Inc.</last-name><address><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Ichim</last-name><first-name>Thomas</first-name><address><city>San Diego</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Bogin</last-name><first-name>Vladimir</first-name><address><city>Portland</city><state>OR</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Medistem, Inc.</orgname><role>02</role><address><city>San Diego</city><state>CA</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The use of endometrial regenerative cells (ERC) and other endometrial originating cells for the treatment of traumatic brain injury is disclosed. In one embodiment a patient is administered a population of CD90 positive, CD105 positive, allogeneic regenerative cells subsequent to a brain injury. Cell concentration, frequency of administration, and route of administration may be determined based on extent of injury, inflammatory response and endogenous stem cell mobilization. In one embodiment, a patient suffering from traumatic brain injury is administered a dose of 100 million Endometrial Regenerative Cells intravenously at a rate of 1 million cells per minute in a volume of 100 ml of saline.</p></abstract></us-patent-application>